Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Read Moreby Selina McKee | Jul 9, 2018 | News | 0
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
Clovis Oncology is seeking to expand use of its PARP inhibitor Rubraca in Europe to include maintenance treatment of certain adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read Moreby Selina McKee | Apr 9, 2018 | News | 0
Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Read Moreby Selina McKee | Mar 28, 2018 | News | 0
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read Moreby Selina McKee | Aug 24, 2016 | News | 0
Clovis’ PARP inhibitor rucaparib will get a speedy review from US regulators as a treatment for patients with certain forms of advanced ovarian cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
